Peter Powchik, SVP Clinical Development & Reg at REGENERON PHARMACEUTICALS INC (REGN), sold 25,000 shares at $418.40 ($10.3M) on 2015-01-02, disclosed to the SEC on 2015-01-05.
Scheduled sale ($10.3M) by SVP Clinical Development & Reg under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $412.78 | 3,151 | $1.3M | 12.6% |
| 2 | $412.78 | 11,027 | $4.6M | 44.0% |
| 3 | $410.99 | 1,400 | $575K | 5.6% |
| 4 | $411.99 | 1,122 | $462K | 4.5% |
| 5 | $412.81 | 1,700 | $702K | 6.8% |
| 6 | $414.07 | 2,758 |
| $1.1M |
| 11.1% |
| 7 | $415.20 | 1,642 | $682K | 6.6% |
| 8 | $416.75 | 900 | $375K | 3.6% |
| 9 | $417.44 | 1,000 | $417K | 4.0% |
| 10 | $418.40 | 300 | $126K | 1.2% |
| Total | $413.34 avg | 25,000 | $10.3M | 100% |
| Filing → |
| REGN | SELL | 2013-12-20 | $2.5M | — | Filing → |
| REGN | SELL | 2013-12-17 | $2K | — | Filing → |
| REGN | SELL | 2013-01-04 | $2.5M | — | Filing → |